Corrected: UK's Kromek posts higher H1 revenue on imaging growth

Kromek

20/01/2026 07:15

Corrects H1 revenue amount in Key Details table to GBP 15 million from GBP 10.76 million

Overview

UK radiation detection firm's H1 revenue rises substantially, driven by Advanced Imaging

Adjusted EBITDA for H1 reaches £6.0 mln, reversing prior loss

Company secured £6.0 mln revolving credit facility to support growth

Outlook

Kromek expects growth in CBRN Detection driven by geopolitical tensions

Company sees favorable conditions for Advanced Imaging with CZT adoption accelerating

Kromek aims to deliver full-year results in line with market expectations

Result Drivers

ADVANCED IMAGING GROWTH - Revenue in Advanced Imaging increased significantly due to the Enablement Agreement with Siemens Healthineers, contributing £8.3m

CBRN DETECTION EXPANSION - Revenue in CBRN Detection more than doubled, driven by strategic execution and market recovery

GROSS MARGIN IMPROVEMENT - Gross margin improved to 71.7% due to high-margin licensing revenue from the Enablement Agreement

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 15 mln


Analyst Coverage

Wall Street's median 12-month price target for Kromek Group PLC is GBP26.00, about 126.1% above its January 19 closing price of GBP11.50

The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nRST5105Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)